Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

icensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent eve
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:10/2/2014)... Research and Markets  has announced the ... by Application, and by Geography - Global Forecast to ... The medical electronics market is expected to grow at ... the world due to growing income levels, and increasing ... hypertension, and cardiovascular diseases. A growing population coupled with ...
(Date:10/2/2014)... 2, 2014  Eli Lilly and Company (NYSE: ... tabalumab­ -- being studied for the treatment of ... -- due to insufficient efficacy in two pivotal ... on safety concerns. ­­­­ In the ... primary endpoint, at either dose studied, of statistically ...
(Date:10/2/2014)...  InfinityQS International, Inc., the global authority on ... client speakers for Infusion Chicago, its 9 th ... will be held Oct. 9-10, 2014, at the ... from Coloplast, The Kellogg Company, Biomet, General Cable, ... two-day event will also include best practice presentations ...
Breaking Medicine Technology:Medical Electronics (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU) Market - Global Forecast to 2020 2Medical Electronics (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU) Market - Global Forecast to 2020 3Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3
... SAN DIEGO, Oct. 4 To mark the beginning ... its breast cancer treatment services at its West Houston ... Emission Mammography) scanners are high-resolution breast PET systems that ... of a lesion.  The metabolic view allows physicians to ...
... ALTOONA, Pa., Oct. 4 In response ... and the importance of "aging-in-place" as an ... Technologies, LLC ("Delta") today announced the introduction ... developed to optimize the homecare therapist. ...
Cached Medicine Technology:SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services 2Delta Health Technologies ClinicalVirtuosoâ„¢ Targets Homecare Therapists 2
(Date:10/2/2014)... Robins & Morton received nine Excellence ... Contractors (ABC) of Alabama. , ABC will recognize ... Sheraton Birmingham Hotel., ,     HealthSouth Rehabilitation ... $25 Million, Obelisk Award (First Place) , ... Million to $25 Million, Obelisk Award (First Place) ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... control -- especially long-acting implanted devices -- could slash pregnancy ... new findings suggest. In a study of 1,400 teenage ... the girls, rates of unplanned pregnancy and abortion. Over three ... -- versus a rate of 158 per 1,000 among all ...
(Date:10/2/2014)... 1, 2014 (HealthDay News) -- Children with autism are ... fully capable of being more active, a small study ... of 29 children, some with autism and some without. ... of moderate physical activity and 70 more minutes each ... children with autism scored lower on strength, but had ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... that pull out all the stops to rescue surgical ... but the cost of such heroism is questionable, a ... 5 percent better at saving elderly patients with life-threatening ... with less intensity, said senior author Dr. Amir Ghaferi. ...
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
Breaking Medicine News(10 mins):Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2
... IntraHealth International will highlight its ... the developing world during the 36th annual ... D.C., May 26-30. Hosted by the Global Health ... = Healthy Communities," focuses on the ways in which ...
... groups, headed by Prof. Nils Brose of the Max Planck ... on behalf of the European Union, to study the role ... the research teams is headed by Prof. Kobi Rosenblum of ... has been awarded a grant of 600,000 Euro. The topic ...
... reports MS medication possession ratio of 86 percent for ... Multiple sclerosis patients managed by a specialty pharmacy program ... risk of being hospitalized for their disease than those ... according to a study completed by HealthCore, Inc.HealthCore researcher ...
... Velocity,s intelligent search capabilities such as geo-spatial search, content ... May 19 Vivisimo ( www.vivisimo.com ), a leading ... that Bupa, an international health and care company with ... selected the Vivisimo Velocity Search Platform ...
... to provide sun protection, laughs and college scholarship ... Today non-profit Cancer for College launches a new ... proceeds from the sunscreen sales will go to ... granting college scholarships to cancer survivors and amputees.To ...
... mice might explain progression from skin to breathing condition ... secreted by eczema-damaged skin might trigger asthma in children, ... study of mice with an eczema-like condition, which suggested ... trigger substance might help prevent asthma. , An estimated ...
Cached Medicine News:Health News:IntraHealth International Addresses Capacity Building and Open Source Technologies at Tech-Themed Global Health Conference 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 3Health News:Vivisimo Powers Site Search on Bupa's Leading Health Information Websites Worldwide 2Health News:Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer 2Health News:Molecule in Skin May Link Eczema and Asthma 2
... cup system has been designed to enhance ... and cluster hole configurations. The objective of ... on three primary modes: Tilt, migration and ... result in initial and long-term fixation. The ...
Optimal solution for normal acetabulum and younger patients....
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: